Understanding the Current Rating
The Strong Sell rating assigned to Johnson Pharmacare Ltd indicates a cautious stance for investors, signalling significant risks and challenges facing the company. This rating is derived from a detailed evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment, helping investors understand the rationale behind the recommendation.
Quality Assessment
As of 10 July 2026, Johnson Pharmacare’s quality grade is categorised as below average. The company’s long-term fundamental strength is weak, primarily due to its high debt burden. The debt-to-equity ratio stands at an alarming 21.32 times, indicating a heavy reliance on borrowed funds. This level of leverage raises concerns about financial stability and the company’s ability to sustain operations without significant risk.
Operating profit growth over the last five years has been modest, with a compound annual growth rate of just 10.91%. While this shows some expansion, it is insufficient to offset the risks posed by the company’s debt profile. Moreover, the company’s ability to service its debt is notably poor, with an average EBIT to interest coverage ratio of only 0.05, signalling that earnings before interest and taxes are barely enough to cover interest expenses.
Valuation Considerations
The valuation grade for Johnson Pharmacare Ltd is classified as risky. The company is currently trading at valuations that reflect significant uncertainty. Negative EBITDA of ₹-42.78 crores further compounds concerns, as it indicates that the company is not generating sufficient earnings from its core operations to cover operating costs.
Over the past year, the stock has delivered a return of -43.53%, reflecting investor apprehension. Profits have deteriorated dramatically, with a decline of approximately 4105% over the same period. This sharp fall in profitability, combined with negative earnings before interest, taxes, depreciation, and amortisation, suggests that the stock is priced to reflect considerable downside risk.
Financial Trend Analysis
The financial trend for Johnson Pharmacare Ltd is currently flat, indicating stagnation in key financial metrics. The company reported disappointing quarterly results in March 2026, with PBDIT (profit before depreciation, interest, and taxes) at its lowest level of ₹-42.70 crores. Similarly, profit before tax excluding other income was ₹-42.92 crores, and earnings per share (EPS) stood at a low of ₹-1.01.
These figures highlight ongoing operational challenges and a lack of positive momentum in the company’s financial performance. The flat trend suggests that there has been little improvement or deterioration recently, but the overall baseline remains weak.
Technical Outlook
The technical grade for Johnson Pharmacare Ltd is bearish. The stock’s price action over various time frames confirms a downward trajectory. As of 10 July 2026, the stock’s returns are negative across all measured periods: 1 day (0.00%), 1 week (-2.04%), 1 month (-7.69%), 3 months (-14.29%), 6 months (-15.79%), year-to-date (-17.24%), and 1 year (-43.53%).
This consistent decline in price reflects weak investor sentiment and technical indicators that suggest further downside risk. The bearish technical outlook reinforces the Strong Sell rating, signalling that the stock is unlikely to recover in the near term without significant changes in fundamentals or market conditions.
Implications for Investors
For investors, the Strong Sell rating on Johnson Pharmacare Ltd serves as a warning to exercise caution. The combination of high leverage, poor profitability, negative cash flow indicators, and a bearish technical setup suggests that the stock carries substantial risk. Investors should carefully consider these factors before initiating or maintaining positions in the company.
While some companies may recover from difficult periods, the current data as of 10 July 2026 does not indicate a clear path to turnaround for Johnson Pharmacare Ltd. The stock’s valuation and financial metrics imply that downside risks outweigh potential rewards at this stage.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Company Profile and Market Context
Johnson Pharmacare Ltd operates within the Diversified Commercial Services sector and is classified as a microcap company. Its market capitalisation remains modest, reflecting its size and scale relative to larger peers. The company’s challenges are compounded by sector dynamics and competitive pressures, which have contributed to its subdued performance.
Investors should note that the Mojo Score for Johnson Pharmacare Ltd currently stands at 12.0, which corresponds to the Strong Sell grade. This score encapsulates the combined assessment of quality, valuation, financial trend, and technical factors, providing a comprehensive view of the stock’s risk profile.
Summary
In summary, Johnson Pharmacare Ltd’s Strong Sell rating as of 29 May 2026 reflects significant concerns about the company’s financial health and market prospects. The latest data as of 10 July 2026 confirms ongoing weaknesses in profitability, leverage, and price momentum. Investors are advised to approach this stock with caution, recognising the elevated risks and limited near-term upside potential.
Careful monitoring of future financial results and market developments will be essential for those considering exposure to Johnson Pharmacare Ltd. Until there is clear evidence of improvement in fundamentals and technical indicators, the Strong Sell rating remains a prudent guide for investment decisions.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
